Combination Treatment With Curcumin and Quercetin of Adenomas in Familial Adenomatous Polyposis

      Background & Aims: Familialadenomatous polyposis (FAP) is an autosomal-dominant disorder characterized by the development of hundreds of colorectal adenomas and eventual colorectal cancer. Regression of adenomas in this syndrome occurs with the administration of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors, but these compounds can have considerable side effects. We evaluated the efficacy of the combination of diet-derived nonprescription supplements curcumin and quercetin to regress adenomas in patients with FAP. Methods: Five FAP patients with prior colectomy (4 with retained rectum and 1 with an ileal anal pouch) received curcumin 480 mg and quercetin 20 mg orally 3 times a day. The number and size of polyps were assessed at baseline and after therapy. The Wilcoxon signed-rank test was used to determine differences in the number and size of polyps. Treatment side effects and medication compliance also were evaluated. Results: All 5 patients had a decreased polyp number and size from baseline after a mean of 6 months of treatment with curcumin and quercetin. The mean percent decrease in the number and size of polyps from baseline was 60.4% (P < .05) and 50.9% (P < .05), respectively. Minimal adverse side effects and no laboratory abnormalities were noted. Conclusions: The combination of curcumin and quercetin appears to reduce the number and size of ileal and rectal adenomas in patients with FAP without appreciable toxicity. Randomized controlled trials are needed to validate these findings.

      Abbreviation used in this paper:

      FAP (familial adenomatous polyposis)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kinzler K.W.
        • Nilbert M.C.
        • Su L.K.
        • et al.
        Identification of FAP locus genes from chromosome 5q21.
        Science. 1991; 253: 661-665
        • Bussey H.J.R.
        Familial polyposis coli. Family studies, histopathology, differential diagnosis, and results of treatment. Johns Hopkins University Press, Baltimore1975
        • Waddell W.R.
        • Loughry R.W.
        Sulindac for polyposis of the colon.
        J Surg Oncol. 1983; 24: 83-87
        • Giardiello F.M.
        • Hamilton S.R.
        • Krush A.J.
        • et al.
        Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.
        N Engl J Med. 1993; 328: 1313-1316
        • Steinbach G.
        • Lynch P.M.
        • Phillips R.K.S.
        • et al.
        The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
        N Engl J Med. 2000; 342: 1946-1952
        • Aggarwal B.B.
        • Kumar A.
        • Bharti A.C.
        Anticancer potential of curcumin.
        Anticancer Res. 2003; 23: 363-398
        • Cheng A.L.
        • Hsu C.H.
        • Lin J.K.
        • et al.
        Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high risk or premalignant lesions.
        Anticancer Res. 2001; 21: 2895-2900
        • Sharma R.A.
        • McLelland H.R.
        • Hill K.A.
        • et al.
        Pharmocodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer.
        Clin Cancer Res. 2001; 7: 1894-1900
        • Hosokawa N.
        • Hosokawa Y.
        • Sakai T.
        • et al.
        Inhibitory effect of quercetin on the synthesis of a possible cell-cycle related 17 KDa protein in human colon cancer cells.
        Int J Cancer. 1990; 45: 1119-1124
        • Deschner E.E.
        • Ruperto J.
        • Wong G.
        • et al.
        Quercetin and rutin as inhibitors of azoxymethanol-induced colonic neoplasia.
        Carcinogenesis. 1991; 12: 1193-1196
        • Deschner E.E.
        • Ruperto J.F.
        • Wong G.Y.
        • et al.
        The effect of dietary quercetin and rutin on AOM-induced acute colonic epithelial abnormalities in mice fed a high-fat diet.
        Nutr Cancer. 1993; 20: 199-204
      1. Cancer Therapy Evaluation Program.
        Common toxicity criteria. National Cancer Institute, Bethesda, MD1998
        • James W.
        • McGannon E.A.
        • Church J.M.
        Incidence of neoplastic polyps in the ileal pouch of patients with FAP after restorative proctocolectomy.
        Dis Colon Rectum. 1998; 41: 552-556
      2. National Toxicology Program (NTP).
        Toxicology and carcinogenesis studies of tumeric oleoresin (CAS No. 8024-37-1) in F344/N rats and B6C3F1 mice. 1993 (Research Triangle, NC: NTP Technical Report Series, No 427)
        • Rao C.V.
        • Rivenson A.
        • Simi B.
        • et al.
        Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound.
        Cancer Res. 1995; 55: 259-266
      3. Quercetin. 2003 PDR for nonprescription drugs and dietary supplements. PDRhealth. Available at:

        • Pereira M.A.
        • Grubbs C.J.
        • Barnes L.H.
        • et al.
        Effects of the phytochemicals, curcumin and quercetin, upon azosymethane-induced colon cancer and 7,12-dimethylbenz (a) anthracene-induced mammary cancer in rats.
        Carcinogenesis. 1996; 17: 1305-1311
        • Kawamori T.
        • Lubet R.
        • Steele V.E.
        • et al.
        Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colorectal cancer.
        Cancer Res. 1999; 59: 597-601
        • Mahmoud N.N.
        • Carothers A.M.
        • Grunberger D.
        • et al.
        Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis.
        Carcinogenesis. 2000; 21: 921-927
        • Piper J.T.
        • Singhal S.S.
        • Salameh M.
        • et al.
        Mechanisms of anticarcinogenic properties of curcumin.
        Int J Biochem Cell Biol. 1998; 30: 445-456
        • Jovanovic S.V.
        • Steenken S.
        • Boone C.M.
        • et al.
        H-atom transfer is a preferred antioxidant mechanism of curcumin.
        J Am Chem Soc. 1998; 121: 9677-9681
        • Plummer S.M.
        • Holloway K.A.
        • Manson M.M.
        • et al.
        Inhibition of cyclooxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kB activation via the NIK/IKK signaling complex.
        Oncogene. 1999; 18: 6013-6020
        • Sharma R.A.
        • Euden S.A.
        • Platton S.L.
        • et al.
        Phase I clinical trial of oral curcumin.
        Clin Cancer Res. 2004; 10: 6847-6854
        • Giardiello F.M.
        • Casero R.A.
        • Hamilton S.R.
        • et al.
        Prostanoids, ornithine decarboxylase and polyamines in primary chemoprevention of familial adenomatous polyposis.
        Gastroenterology. 2004; 126: 425-431
        • Kuo M.L.
        • Yang N.C.
        Reversion of v-H-ras-transformed NIH 3T3 cells by apigenin through inhibiting mitogen activated protein kinase and its downstream oncogenes.
        Biochem Biophys Res Commun. 1995; 212: 767-775
        • Ranelletti F.O.
        • Maggiano N.
        • Serra F.G.
        • et al.
        Quercetin inhibits p21-RAS expression in human colon cancer cell lines and in primary colorectal.
        Int J Cancer. 2002; 85: 438-445